Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its product candidate, OP-1250, is a novel oral therapy with combined activity as both a complete ER antagonist, or CERAN, and a selective ER degrader, or SERD, which is believed to drive deeper, more durable responses than existing therapies. The company was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA. |  |
|
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| CLARK IAN T | Director | Dec 19 '25 | Option Exercise | 4.61 | 264,800 | 1,219,544 | 264,800 | Dec 23 09:42 PM | | CLARK IAN T | Director | Dec 19 '25 | Sale | 29.73 | 264,800 | 7,873,109 | 0 | Dec 23 09:42 PM | | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Dec 19 '25 | Sale | 30.46 | 51,000 | 1,553,544 | 551,881 | Dec 23 09:41 PM | | Zojwalla Naseem | Chief Medical Officer | Dec 22 '25 | Option Exercise | 14.07 | 50,000 | 703,392 | 153,997 | Dec 23 09:40 PM | | Zojwalla Naseem | Chief Medical Officer | Dec 19 '25 | Option Exercise | 15.25 | 40,000 | 610,000 | 173,997 | Dec 23 09:40 PM | | Zojwalla Naseem | Chief Medical Officer | Dec 23 '25 | Option Exercise | 7.02 | 50,000 | 351,000 | 103,997 | Dec 23 09:40 PM | | Zojwalla Naseem | Chief Medical Officer | Dec 22 '25 | Sale | 28.04 | 100,000 | 2,804,000 | 53,997 | Dec 23 09:40 PM | | Zojwalla Naseem | Chief Medical Officer | Dec 23 '25 | Sale | 27.66 | 99,509 | 2,752,419 | 4,488 | Dec 23 09:40 PM | | Zojwalla Naseem | Chief Medical Officer | Dec 19 '25 | Sale | 28.20 | 70,000 | 1,973,729 | 103,997 | Dec 23 09:40 PM | | Zojwalla Naseem | Officer | Dec 23 '25 | Proposed Sale | 27.66 | 99,509 | 2,752,165 | | Dec 23 01:31 PM | | Harmon Cyrus | Officer | Dec 22 '25 | Proposed Sale | 28.53 | 2,881 | 82,182 | | Dec 22 04:09 PM | | Zojwalla Naseem | Officer | Dec 22 '25 | Proposed Sale | 28.04 | 100,000 | 2,804,039 | | Dec 22 02:14 PM | | Myles David C. | Officer | Dec 19 '25 | Proposed Sale | 30.46 | 51,000 | 1,553,447 | | Dec 19 04:33 PM | | Zojwalla Naseem | Officer | Dec 19 '25 | Proposed Sale | 28.19 | 70,000 | 1,973,561 | | Dec 19 04:29 PM | | CLARK IAN T | Director | Dec 19 '25 | Proposed Sale | 29.73 | 264,800 | 7,873,502 | | Dec 19 02:35 PM | | RAPPAPORT ANDREW | Director | Nov 21 '25 | Option Exercise | 0.39 | 35,868 | 13,989 | 35,868 | Nov 25 06:00 PM | | Harmon Cyrus | Director | Sep 18 '25 | Sale | 8.33 | 10,000 | 83,300 | 744,140 | Sep 18 09:30 PM | | Harmon Cyrus | Director | Sep 16 '25 | Sale | 8.04 | 10,000 | 80,400 | 754,140 | Sep 18 09:30 PM | | Harmon Cyrus | Director | Sep 18 '25 | Sale | 8.32 | 3,086 | 25,676 | 117,028 | Sep 18 09:30 PM | | Harmon Cyrus | Director | Sep 16 '25 | Sale | 8.08 | 1,914 | 15,465 | 120,114 | Sep 18 09:30 PM | | Harmon Cyrus | Director | Sep 18 '25 | Proposed Sale | 8.33 | 13,086 | 108,978 | | Sep 18 02:08 PM | | Harmon Cyrus | Director | Sep 16 '25 | Proposed Sale | 8.04 | 11,914 | 95,827 | | Sep 16 04:39 PM | | Bain Capital Life Sciences Inv | 10% Owner | Jan 08 '25 | Buy | 5.76 | 300,000 | 1,727,370 | 7,800,000 | Jan 13 04:34 PM |
|
